Morgan Stanley analyst Michael Ulz reiterated an Equalweight rating and $100.00 price target on Mirati Therapeutics (NASDAQ: MRTX)The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE